Kunming Longjin Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002750.SZ

Kunming Longjin Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2023: USD 12.20 M

Kunming Longjin Pharmaceutical Co., Ltd. Revenue is USD 12.20 M for the year ending December 31, 2023, a -31.53% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Kunming Longjin Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2022 was USD 17.82 M, a -83.88% change year over year.
Kunming Longjin Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2021 was USD 110.56 M, a 184.10% change year over year.
Kunming Longjin Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2020 was USD 38.92 M, a -1.56% change year over year.
Kunming Longjin Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2019 was USD 39.53 M, a -19.08% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shenzhen Stock Exchange: 002750.SZ

Kunming Longjin Pharmaceutical Co., Ltd.

CEO	Mr. Ya He Li
IPO Date	March 24, 2015
Location	China
Headquarters	NO.789, Lanmao Road
Employees	285
Sector	Health Care
Industries Pharmaceuticals Paper & Forest Products

Description

Kunmig Longjin Pharmaceutical Co., Ltd. develops, produces, and sells natural botanicals and chemical freeze-dried powder injections in China. The company offers Chinese, biochemical, chemical, cardio-cerebral vascular, and digestive system medicines; immune system and first aid medications; and vitamins, minerals, and enteral and parenteral nutrition products. It also engages in the industrial hemp plantation business. The company was founded in 1996 and is headquartered in Kunming, China.

Key trends

Past 5 years